Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
넥스트젠바이오사이언스 logo — Pioneering breakthroughs in fibrosis treatment with innovati...

넥스트젠바이오사이언스

Pioneering breakthroughs in fibrosis treatment with innovative drugs tailored for various unmet medical needs across multiple diseases.

Founded 2018 4 employees Biopharma, Health Care +1

General Information

Company Name 넥스트젠바이오사이언스
Founded Year 2018
Employees 4
Industries Biopharma, Health Care, Life Sciences
Social

Get notified when 넥스트젠바이오사이언스 moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About 넥스트젠바이오사이언스

Nextgen Bioscience is a biopharmaceutical company founded in 2018 with a focus on pioneering breakthroughs in fibrosis treatment. Their innovative drugs are specifically tailored to address unmet medical needs across multiple diseases. The company's platform includes potential compounds targeting three significant diseases: wet macular degeneration, non-alcoholic steatohepatitis (NASH), and pulmonary fibrosis. Moreover, Nextgen Bioscience provides treatment for ocular fibrosis disease, effectively addressing the unmet medical needs of refractory fibrosis patients who lack effective treatment options. The company operates within the Biopharma, Health Care, and Life Sciences industries, demonstrating its commitment to improving healthcare outcomes through innovative drug development. With a focus on clinical trials for a therapeutic drug aimed at fibrosis treatment, the company positions itself at the forefront of cutting-edge medical research and advancement. These factors make Nextgen Bioscience an intriguing prospect for potential venture capital investment. Their dedication to addressing unmet medical needs in the field of fibrosis treatment, combined with a focus on clinical trials and targeted drug development, presents a compelling investment opportunity within the rapidly evolving biopharmaceutical industry. While specific details regarding the company's headquarter, last investment, and investors are not provided, the potential breakthroughs in fibrosis treatment make Nextgen Bioscience a promising candidate for venture capital consideration.

Taxonomy: pharmaceutical company, clinical trials, therapeutic drug, fibrosis treatment, wet macular degeneration, non-alcoholic steatohepatitis, NASH, pulmonary fibrosis, ocular fibrosis disease, drug development, innovative drugs, biopharmaceuticals, medical breakthroughs, unmet medical needs, refractory fibrosis

No funding data available for 넥스트젠바이오사이언스 yet.

Get notified when 넥스트젠바이오사이언스 raises funding

넥스트젠바이오사이언스 Alternatives & Competitors

넥스트젠바이오사이언스 vs
Kither Biotech
Kither Biotech Italy

Improving treatment for patients suffering from incurable respiratory diseases

Series B
18 employees
Biopharma, Biotechnology
넥스트젠바이오사이언스 vs
LinXis Biopharmaceuticals
LinXis Biopharmaceuticals The Netherlands

We target the cells that drive fibrosis

20 employees
Biotechnology, Health Care
넥스트젠바이오사이언스 vs
MDI Therapeutics, Inc.
MDI Therapeutics, Inc. United States

Developing novel serpin-based therapies

Series A
5 employees
Biotechnology, Health and Wellness

FAQ About 넥스트젠바이오사이언스

Pioneering breakthroughs in fibrosis treatment with innovative drugs tailored for various unmet medical needs across multiple diseases.
넥스트젠바이오사이언스 was founded in 2018.
넥스트젠바이오사이언스 operates in the following industries: Biopharma, Health Care, Life Sciences.
넥스트젠바이오사이언스 has approximately 4 employees.
Top alternatives and competitors to 넥스트젠바이오사이언스 include Kither Biotech, LinXis Biopharmaceuticals, MDI Therapeutics, Inc., Tract Bio, Lung Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
넥스트젠바이오사이언스 and Kither Biotech are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors 넥스트젠바이오사이언스 and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy